SHIJIAZHUANG, China, Aug. 11, 2020 /PRNewswire/ -- Yiling Pharmaceutical Co., Ltd. announced on Monday that it has received a drug registration certificate issued by the Food and Drug Administration of the Philippines, indicating Lianhua Qingwen Capsule has been registered in accordance with the standards for Traditionally-used Herbal Product.
As a leading product of Yiling Pharmaceutical Co., Ltd., Lianhua Qingwen products are mainly used for the treatment of cold and flu-related diseases, and have been listed in the diagnosis and treatment schemes for cold and flu-related diseases by the National Health Commission of China and National Administration of Traditional Chinese Medicine of China successively many times. In 2020, Lianhua Qingwen Capsule / Granule has been listed as a recommended medicine for the epidemic in the Diagnosis and Treatment Scheme of Novel Coronavirus Pneumonia (Interim Versions #4-#7), issued officially by the related Chinese authorities. On April 12, 2020, the National Medical Products Administration of China approved that a new indication for "mild and common COVID-19" was added to Lianhua Qingwen Capsule/ Granule on the basis of its originally approved indications.
Up to now, Lianhua Qingwen Capsule has been approved for launch on the market in more than 10 countries and regions including Brazil, Indonesia, Canada, Romania and Thailand.
The Department of Health (DOH) of the Philippines on Monday reported a single-day increase in new COVID-19 cases at 6,958. Based on DOH's latest COVID-19 bulletin, the country's coronavirus caseload now stands at 136, 638.
